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Abstract 25 
Tedizolid (TZD) is a second-generation oxazolidinone and demonstrates potent in-vitro 26 
activity against multidrug-resistant Gram-positive bacteria. Phase III studies in patients 27 
with acute bacterial skin and skin structure infections (ABSSSI) have demonstrated the 28 
non-inferiority of TZD to linezolid (LZD). However, there are only a few studies that 29 
show the effect of TZD in pulmonary infections. In this study, we investigated the effect 30 
of TZD in a murine model of hematogenous pulmonary infection caused by 31 
methicillin-resistant Staphylococcus aureus (MRSA). The mice were treated either 32 
twice daily with saline (control), 25 mg/kg of vancomycin (low-VAN), 110 mg/kg of 33 
vancomycin (high-VAN), 120 mg/kg of LZD or once daily with 20 mg/kg of TZD. As 34 
compared to the control, the low- and high-VAN treatment groups, LZD and TZD 35 
significantly improved the survival rate, reduced the bacterial count in the lungs. 36 
Furthermore, TZD decreased the area of central bacterial colony zone (CBCZ) at 36 37 
hours post-inoculation, compared with the control. In addition, we investigated the 38 
immunomodulatory effect of TZD by evaluating the plasma concentrations of the 39 
inflammatory cytokines. Although there were no significant differences in the bacterial 40 
count in the lungs amongst the drugs at 26 hours post-inoculation, TZD and LZD 41 
significantly improved the plasma concentrations of TNF-alpha, IL-6 and MIP-2, in 42 
comparison with the control. In this study, both TZD and LZD demonstrated 43 
antimicrobial and immunomodulatory efficacy in a murine model of hematogenous 44 
pulmonary infection caused by MRSA. 45 
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Introduction 47 
Methicillin-resistant Staphylococcus aureus (MRSA) was first identified in the 1960s, 2 48 
years after the initiation of the clinical use of methicillin. Since then, MRSA has spread 49 
worldwide and is a significant pathogen associated with many nosocomial and 50 
healthcare-associated infections, such as bacteremia, endocarditis, pneumonia, and skin 51 
and soft tissue infections (Liu, et al., 2012). Recently, panton-valentine leukocidin 52 
(PVL)-positive community-associated (CA)-MRSA, especially the USA300 strain, is 53 
widespread in the community- and hospital settings (Grudmann, et al., 2006; 54 
Holzknecht, et al., 2010; Popovich, et al., 2008). Thus, MRSA infections are diseases of 55 
emerging importance, which need our attention for effective treatment.  56 
During the past decade, several anti-MRSA agents have been developed. Among these, 57 
linezolid (LZD), the first-generation oxazolidinone, has certain distinct characteristics: 58 
its mechanism of action is by inhibition of protein synthesis; its oral bioavailability is 59 
100%; its tissue penetration, including into the epithelial lining fluid (ELF) of the lungs 60 
and the infected skin and soft tissues, is good (Liu, et al., 2012; Rodvold and 61 
McConeghy, 2014). Additionally, LZD showed an immunomodulatory effect, such as 62 
inhibition of the inflammatory cytokine production (Yoshizawa, et al., 2012; 63 
Sharma-Kuinkel, et al., 2013; Zargoulidis, et al., 2012). In the published guidelines for 64 
the treatment of MRSA infection, LZD is one of the first-line agents for the treatment of 65 
skin and soft-tissue infections, pneumonia and bone and joint infections caused by 66 
MRSA (Liu, et al., 2012). However, some outbreaks of LZD-resistant pathogens have 67 
been reported (Gu, et al., 2013). 68 
Tedizolid (TZD) is a second-generation oxazolidinone and has demonstrated potent 69 
in-vitro activity against multidrug-resistant Gram-positive bacteria, including some 70 
LZD-resistant strains (Locke, et al., 2014a; Sham DF, et al., 2015; Locke, et al.; 2014b). 71 
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In several clinical trials in patients with acute bacterial skin and skin structure infections 72 
(ABSSSI), 200 mg of TZD administered once daily for 6 days showed non-inferiority to 73 
600 mg of LZD administered twice daily for 10 days (Prokocimer, et al., 2013; Moran, 74 
et al., 2014; Shor, et al., 2015) and had fewer side effects. Based on the results, TZD 75 
was approved in the treatment of patients with ABSSSI in the United States and Europe. 76 
Despite the fact that TZD and LZD penetrated both, the ELF and the alveolar 77 
macrophages in the lungs, there are few studies regarding the efficacy of TZD in 78 
pulmonary infections, including pneumonia (Tessier, et al., 2012; Lepak, et al., 2012). 79 
The purpose of this study was to demonstrate the in-vivo efficacy of TZD in a murine 80 
model of hematogenous pulmonary infection caused by MRSA. 81 
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Material and methods 83 
Bacterial strain: 84 
The MRSA strain used in this study was NUMR101, a clinical isolate obtained from the 85 
blood sample of a patient at the Nagasaki University Hospital (Yanagihara, et al., 2008). 86 
The genetic characteristic of NUMR101 was identified by real-time polymerase chain 87 
reaction (PCR) using the same method as described in a previous report (Motoshima, et 88 
al., 2010). The multilocus sequence typing (MLST) was performed according to the 89 
previous study (Enright, et al., 2010). Sequence types (STs) were assigned to clusters 90 
using the MLST database (http://www.mlst.net). The bacteria were stored at -80°C in a 91 
Microbank® bead preservation system (Pro-Lab Diagnostics, Ontario, CA) until use. 92 
 93 
Antimicrobial agents: 94 
TZD was supplied by Bayer HealthCare AG, (Leverkusen, Germany). LZD injection 95 
2mg/ml and vancomycin (VAN) powder for solution for infusion were purchased from 96 
Pfizer Inc., (Tokyo, Japan) and Shionogi & Co., LTD., (Osaka, Japan), respectively. 97 
TZD was diluted in dimethyl sulfoxide (DMSO) and stored at -20°C until use. For the 98 
treatment of the MRSA infection in the murine model, TZD, which was dissolved in 99 
DMSO and VAN powder for solution for infusion were diluted in normal saline, which 100 
is equivalent to the fluid volumeof LZD injection. In an antimicrobial susceptibility test, 101 
LZD powder for solution was supplied by Pfizer, Inc., (Groton, CT). LZD powder for 102 
solution and TZD were weighed and diluted in DMSO. 103 
 104 
Antimicrobial susceptibility test: 105 
 6
We tested the minimum inhibitory concentrations of VAN, LZD and TZD against the 106 
NUMR101 strain by a micro-dilution method, in accordance with the guidelines of the 107 
Clinical and Laboratory Standards Institute (Clinical and Laboratory Standards Institute, 108 
2012). We weighed the antimicrobial agents and diluted in DMSO at 1.6 mg/ml and 109 
performed a two-fold serial dilution of the 1.6mg/ml stock in DMSO to obtain a 50X 110 
working solution. From the 50X stock dilution, we added 2 μl volume to a 96-well 111 
assay plate containing 98 μl of cation-adjusted, Mueller Hinton II broth (Becton 112 
Dickson and Company, Sparks, MD), with the NUMR101 strain premixed at 5x105 113 
CFU/ml. We incubated the plates overnight at 37°C with 5% CO2 and analyzed them 114 
after incubation. 115 
 116 
Animals: 117 
We purchased specific-pathogen-free ddY male mice (6-week-old, 25 to 30 g body 118 
weight) from Japan SLC, Inc., Shizuoka, Japan. The mice were housed in a 119 
pathogen-free environment and received sterile food and water in the Biomedical 120 
Research Center at Nagasaki University. 121 
 122 
Inoculum: 123 
The method of inoculation has been previously reported (Sawai, et al., 1997). Briefly, 124 
we cultured the MRSA strain overnight in the Mueller-Hinton II agar at 37°C with 5% 125 
CO2 in 100% humidity. After incubation, we suspended the bacteria in normal saline, 126 
centrifuged them at 3000 rpm at 4°C for 10 min and further, re-suspended them in 127 
normal saline followed by dilution to a bacterial count of 5x109 CFU/ml. We mixed 10 128 
ml of this suspension with 10 ml of 4% molten Noble agar (Difco Laboratories, Detroit, 129 
MI) at 45°C. We placed 1.0 ml of the agar-bacterium suspension into a 1.0 ml syringe 130 
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and rapidly injected it into 49 ml of rapidly stirred, ice-cooled normal saline via a 131 
26-gauge needle. This resulted in the solidification of the agar droplets into beads of 132 
approximately 250 μm in diameter. The final bacterial count was 5x107 CFU/ml. 133 
 134 
Murine model of hematogenous pulmonary infection: 135 
The Ethics Review Committee for Animal Experimentation approved all the 136 
experimental protocols used in this study. The method used for inducing infection has 137 
been reported previously (Sawai, et al., 1997). Briefly, we injected 0.25 ml of the 138 
suspension containing agar beads with a bacterial count of 1.25x107 CFU/mice, into the 139 
tail vein of the mice. After 24 hours-post inoculation, a septic embolous of 140 
Staphylococcus aureus enmeshed in agar beads was detected in the pulmonary artery 141 
with inflammatory cell accumulation in its wall (Sawai, et al., 1997). 142 
 143 
Treatment protocol: 144 
We used the antimicrobial agents for the treatment, 24 hours post-inoculation, at an 145 
interval of every 12 hours (q12h) or every 24 hours (q24h), by intra-peritoneal injection. 146 
We treated the mice with normal saline q12h (control), 25 mg/kg of VAN q12h 147 
(low-VAN), 110 mg/kg of VAN q12h (high-VAN), 120 mg/kg of LZD q12h or 20 148 
mg/kg of TZD q24h. At the mentioned doses of these antimicrobial agents, the 149 
concentrations of these drugs after the ELF exposure in mice, were similar to those in 150 
humans, following intravenous regimens of 1 g of VAN q12h, 600 mg of LZD q12h and 151 
200 mg of TZD q24h (Tessier, et al., 2012). We injected the dose of high-VAN in mice 152 
to simulate the area under the curve in the concentrations versus time plot for the 153 
estimation of the free drug in plasma, which is the unbound fraction of drug, observed 154 
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following an intravenous regimen of 1 g of VAN q12h in humans (Crandon, et al., 155 
2010).  156 
 157 
Histopathological and bacteriological examinations: 158 
The method of histopathological and bacteriological examinations have been previously 159 
described (Kihara, et al., 2009; Harada, et al., 2013). We sacrificed the mice at specific 160 
time intervals by cervical dislocation and subsequently, dissected them to remove the 161 
lungs under aseptic conditions. We fixed the lungs in 10% formalin neutral buffer 162 
(Wako Pure Chemical Industries, Ltd., Osaka, Japan) and stained them with 163 
hematoxylin-eosin. We suspended the lungs used for the bacteriological analysis, in 1 164 
ml of normal saline and homogenized it with a homogenizer (AS One Co., Osaka, 165 
Japan). We collected the blood by a right ventricular puncture, using heparin-coated 166 
syringes. Subsequently, we cultured the lungs and the blood quantitatively by serial 167 
dilutions in the Mueller-Hinton II agar plates. After overnight incubation, we evaluated 168 
the number of visible colonies. The lowest level of detectable bacterial count was 1x 102 169 
CFU/ml. 170 
 171 
Cytokine ELISA: 172 
We collected the blood by a right ventricular puncture, using heparin-coated syringes. 173 
We separated the plasma by centrifugation and assayed the concentrations of tumor 174 
necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta), interleukin-6 (IL-6) and 175 
macrophage inflammatory protein 2 (MIP-2) in the plasma, using the mouse cytokine 176 




Statistical analysis:  180 
We used a statistical software package (StatMate V; ATMS Co., Ltd., Tokyo, Japan) for 181 
all the statistical comparisons and calculated the survival rates using the Kaplan-Meier 182 
method. We performed the survival analysis using the log-rank test and expressed the 183 
data as mean and standard deviation (SD). In the graph of the bacterial count in the 184 
lungs and the blood, we depicted the data by the box-and-whisker plot and analyzed the 185 
differences between the groups using the one-way analysis of variance with the Tukey’s 186 
post-hoc test. All the tests of significance were two-tailed and the alpha level for 187 
denoting statistical significance was set at < 0.05. 188 
 189 
  190 
 10
Results 191 
Genetic characteristics of the NUMR101: 192 
The staphylococcal cassette chromosome mec (SCCmec) of the strain was type II. The 193 
strain carried virulence genes such as sec and tsst but did not carry etb and pvl genes. In 194 
the MLST, the allelic profile of arcC, aroE, glpF, gmk, pta, tpi and yqiL were 1, 4, 1, 4, 195 
12, 1, 10, respectively. The sequence type of the NUMR101 strain was 5. 196 
 197 
MICs of the antimicrobial agents against the NUMR101: 198 
The MICs of VAN, LZD and TZD against the bacterial strain were 1.0, 0.5, and 1.0 199 
mg/L, respectively. 200 
 201 
Murine model of hematogenous pulmonary infection: 202 
At the beginning of the treatment, 24 hours post-inoculation, the bacterial count in the 203 
lungs of the mice was 8.39 ± 0.35 log10 CFU/ml (n=6). Simultaneously, during the 204 
histopathological examination conducted by microscopy (n=3), many abscess lesions 205 
with the central bacterial colony zone (CBCZ) were observed, surrounded by 206 
inflammatory cells (Fig. 1). 207 
 208 
Therapeutic effects of antimicrobial agents on survival rate: 209 
In the survival study, the mice were treated by the prescribed methods until 120 hours 210 
post-inoculation and the survival rates were observed until 132 hours post-inoculation 211 
(n=6 in each group). The survival rates were significantly higher in the LZD- and the 212 
TZD-treatment groups at 83.3% and 100%, respectively, than those in the low-VAN 213 
treatment group (0.0%) (P = 0.002 versus LZD and P < 0.001 versus TZD) and the 214 
control group (16.7%) (P = 0.010 versus LZD and P = 0.004 versus TZD) (Fig. 2). 215 
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High-VAN could improve the survival rate by 50.0% but there were no significant 216 
differences when the high-VAN treatment group was compared with the control and the 217 
low-VAN treatment group. 218 
 219 
Histopathological and bacteriological examinations: 220 
The mice were sacrificed 36 hours post-inoculation i.e., 12 hours after the initial 221 
treatment. The lung specimens were used for the histopathological examination (n=4 in 222 
each group). In both the LZD- and the TZD-treatment groups, the area of the CBCZ had 223 
decreased, whereas, especially in the TZD treatment group the CBCZ had been 224 
eliminated from many abscess lesions (Fig. 3e). In contrast, such abscesses without the 225 
CBCZ were few in the low-VAN-, the high-VAN-, and the LZD-treatment groups (Fig. 226 
3b, c, d). In the LZD treatment group, the area of the CBCZ had decreased, but had not 227 
been eliminated. 228 
Simultaneously, the bacterial count in the lungs and the blood were evaluated (n=5 in 229 
each group). The bacterial count in the lungs had significantly decreased in the LZD- 230 
and the TZD-treatment groups to 7.47 ± 0.37 log10 CFU/ml (P < 0.05 versus. control) 231 
and 7.23 ± 0.81 log10 CFU/ml (P < 0.05 versus control), respectively, whereas, the 232 
control showed a count of 8.17 ± 0.16 log10 CFU/ml (Fig. 4a). In contrast, there were no 233 
statistically significant differences in the low-VAN- and the high-VAN treatment groups, 234 
showing a bacterial count of 8.03 ± 0.21 CFU/ml and 7.87 ± 0.24 log10 CFU/ml, 235 
respectively, when compared with the control group. The bacterial count in the blood 236 
had significantly decreased in the high-VAN- and the TZD-treatment groups showing a 237 
count of 2.88 ± 0.67 CFU/ml and 2.95 ± 0.75 log10 CFU/ml, respectively, in comparison 238 
with the control group (4.51 ± 0.42 log10 CFU/ml; P < 0.05 versus high-VAN- and TZD- 239 
treatment groups) (Fig. 4b). In comparison with the control group, the low-VAN and 240 
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LZD did not decrease the bacterial count in the blood, showing a count of 4.33 ± 1.18 241 
log10 CFU/ml and 3.69 ± 0.49 log10 CFU/ml, respectively. 242 
Since there was a conflict between the histopathological evaluation and the 243 
bacteriological examination in the lungs in the LZD treatment group at 36 hours 244 
post-inoculation, the mice were sacrificed and the lung specimens were used for 245 
histopathological examination at 60 hours post-inoculation (n=3 in each group). During 246 
this time, the CBCZ had vanished from many abscess lesions in the LZD- and the 247 
TZD-treatment groups (Fig. 5d, e). 248 
 249 
Inflammatory cytokines in the plasma: 250 
To eliminate the influence of the decrease in the number of bacteria, the mice were 251 
sacrificed 26 hours post-inoculation i.e., 2 hours after the initial treatment. The blood 252 
was collected by a right ventricular puncture, using heparin-coated syringes, and the 253 
plasma concentrations of TNF-alpha, IL-1beta, IL-6 and MIP-2 were evaluated by 254 
ELISA (n=5 in each group). Although there were no significant differences in the 255 
bacterial count in the lungs and the blood between all the groups during this time (data 256 
are not shown), the plasma concentrations of TNF-alpha, IL-6 and MIP-2 significantly 257 
decreased in the LZD- and the TZD-treatment groups in comparison with the control 258 
(Fig. 6a, c, d). There were no differences in the plasma concentration of IL-1beta (Fig. 259 
6b). In the high-VAN treatment group, only the concentration of IL-6 significantly 260 
decreased in comparison with the control (Fig. 6c). 261 
 262 
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Discussion 264 
In this study, we used a murine model of hematogenous pulmonary infection to assess 265 
the effect of the antimicrobial agents on MRSA. Our previous study demonstrated the 266 
superiority of LZD over VAN against MRSA (NUMR101), vancomycin-insensitive S. 267 
aureus (VISA) or PVL-positive CA-MRSA (Yanagihara, et al., 2002; Yanagihara, et al., 268 
2009). In this study, amongst all the antimicrobial agents, LZD and TZD significantly 269 
improved the survival rate, bacterial count in the lungs and the blood, and 270 
histopathological results, compared to the control. In contrast, low-VAN did not show 271 
an improvement for the same parameters. High-VAN significantly improved the 272 
bacterial count in the blood, but could not improve the other evaluation parameters.  273 
 274 
In comparison to low-VAN, LZD and TZD significantly improved the survival rates and 275 
the bacterial count in the lungs. The studied doses of low-VAN, LZD and TZD showed 276 
similar pharmacokinetics to those after ELF exposures in humans, following 277 
intravenous regimens of 1 g of VAN q12h, 600 mg of LZD q12h and 200 mg of TZD 278 
q24h (Tessier, et al., 2012). Since the mice ELF exposures (AUC0-24) for LZD was 279 
approximately 9-fold higher than that for low-VAN (Tessier, et al., 2012), LZD showed 280 
superior efficacy to low-VAN. On the other hand, the mice ELF exposures (AUC0-24) 281 
for TZD was almost equal to that of low-VAN. Considering that the MICs of VAN and 282 
TZD were same, TZD might have a more potent antimicrobial activity than VAN. 283 
 284 
The dose of high-VAN was selected to simulate the area under the curve in the 285 
concentration-time plot for estimation of the free drug in the plasma i.e., the unbound 286 
fraction of the drug, observed following an intravenous regimen of 1 g of VAN q12h in 287 
humans (Crandon, et al., 2010). Compared with the control and the low-VAN treatment 288 
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groups, high-VAN significantly reduced the bacterial count in the blood. However, 289 
high-VAN could not reduce the bacterial count in the lungs and the number of abscesses 290 
with the CBCZ observed during the histopathological analysis, compared with the 291 
control and the low-VAN treatment group. Based on these results, high-VAN was 292 
effective in the treatment of MRSA-induced bacteremia, but not in the treatment of lung 293 
abscesses. Furthermore, compared with LZD and TZD, high-VAN could not improve 294 
the survival rate, the bacterial count in the lungs and the number of abscesses with the 295 
CBCZ observed during the histopathological analysis. Thus, LZD and TZD were more 296 
effective than high-VAN in the murine model of hematogenous pulmonary infection.  297 
There were almost no significant differences in the antimicrobial effect between the 298 
LZD- and the TZD-treatment groups. There were no differences between the LZD- and 299 
the TZD-treatment groups in the reduction of the bacterial count in the lungs and the 300 
blood. Additionally, at 36 hours after initial treatment, LZD as well as TZD vanished the 301 
CBCZ from many abscess lesions. However, during the histopathological analysis at 12 302 
hours after the initial treatment, slight differences were observed between the both drugs. 303 
TZD could eliminate the CBCZ from many lung abscesses, whereas LZD could not. 304 
In addition to the comparison of the antimicrobial effects of the drugs, the plasma 305 
concentrations of the inflammatory cytokines were also compared in this study. At 2 306 
hours after initial treatment, LZD and TZD significantly reduced the plasma 307 
concentrations of TNF-alpha, IL-6, and MIP-2 in comparison with control. Previous 308 
studies have reported that LZD reduced the lipopolysaccharide-induced cytokine 309 
production from peripheral blood mononuclear cells directly (Garcia-Roca, et al., 2006; 310 
Lambers, et al., 2010; Takahashi, et al, 2010). Such a direct immunomodulatory effect 311 
of LZD was observed in the airway epithelial cells, as well (Kaku, et al., 2014). Since 312 
there were no significant differences in the bacterial count in the lungs and the blood 313 
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between the treatment groups at 2 hours after initial treatment, we assume that LZD and 314 
TZD showed direct immunomodulatory effect in this study. However, some studies 315 
reported that the inhibition of the MRSA-induced inflammatory cytokines production 316 
by LZD was associated with the reduction in the bacterial count or toxin production 317 
(Yoshizawa, et al., 2012; Sharma-Kuinkel, et al., 2013; Zargoulidis, et al., 2012; 318 
Yanagihara K, et al., 2002). Therefore, there is a possibility that LZD and TZD showed 319 
indirect immunomodulatory effect associated with the reduction in the toxin production. 320 
 321 
There were some limitations in this study. First, the mouse species were different from 322 
the previous study on pharmacokinetic analysis of low-VAN, LZD, and TZD (Tessier, 323 
et al., 2012). Second, both mouse species and route of administrations were different 324 
from the previous study on pharmacokinetic analysis of high-VAN (Crandon, et al., 325 
2010). Since there is a possibility that these differences differ the pharmacokinetic 326 
results of antimicrobial agents in this study from the previous studies, pharmacokinetic 327 
analysis in this model are needed. Third, we used only one clinical strain in this study. 328 
Fourth, it remains unknown whether LZD and TZD cured the mouse or not because we 329 
examined until a short period of time. Finally, the mechanisms of the 330 
immunomodulatory effect of LZD and TZD remain unknown. Accordingly, more 331 
experimental studies are needed to confirm the effects of TZD in a pulmonary infection. 332 
 333 
Conclusions 334 
In conclusion, we showed that TZD, a second-generation oxazolidinone, had 335 
antimicrobial and immunomodulatory effects in a murine model of hematogenous 336 
pulmonary infection caused by MRSA. Thus, TZD could be considered to be clinically 337 
effective in patients with pulmonary infection caused by MRSA. 338 
 16
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Fig. 1. Histopathological examination of the lungs before the start of the treatment: 
Representative data from each group, at 24 hours post-inoculation of NUMR101 are shown 
(n = 3). Many abscess lesions with the central bacterial colony zones (CBCZ) surrounded by 
the inflammatory cells were observed. Hematoxylin and eosin stain; original magnification, 
x40 (a), x200 (b) and x1000 (c)























Fig. 2. Effects of the antimicrobial agent on the survival rate: 
The mice were treated with normal saline q12h (control), 25 mg/kg of vancomycin q12h (low-
VAN), 110 mg/kg of vancomycin q12h (high-VAN), 120mg/kg of linezolid q12h (LZD) or 20 
mg/kg of tedizolid q24h (TZD). The survival rates were observed until 132 hours post-
inoculation (n = 6 in each group). The survival rates in the TZD- and LZD-treatment groups 
were significantly higher than those in the control and the low-VAN groups. Asterisk, P = 
0.004 versus control and P < 0.001 versus low-VAN for the TZD treatment group. Double 




Fig. 3. Histopathological examination of the lung specimens 12 hours after the initial 
treatment: 
The mice were treated once with normal saline (control), 25 mg/kg of vancomycin (low-
VAN), 110 mg/kg of vancomycin (high-VAN), 120 mg/kg of linezolid (LZD) or 20 mg/kg of 
tedizolid (TZD). Twelve hours after the initial treatment, the mice were sacrificed. The 
representative data are shown (n = 4). In the LZD- and the TZD-treatment groups, the area 
of the central bacterial colony zone (CBCZ) decreased (d), (e). Especially in the TZD 
treatment group, the CBCZ was eliminated from many abscess lesions (e). In contrast, such 
abscesses without CBCZ were few in the low-VAN treatment group (b) and the high-VAN 
treatment group (c).
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x40 x40 x40
x40 x40
Abscess with central 
bacterial colony zone 
Abscess without central 
bacterial colony zone 
Fig. 4. Bacterial count in the lungs and the blood:
The mice were treated with normal saline q12h (control), 25 mg/kg of vancomycin q12h (low-
VAN), 110 mg/kg of vancomycin q12h (high-VAN), 120 mg/kg of linezolid q12h (LZD), or 20 
mg/kg of tedizolid q24h (TZD). Twelve hours after the initial treatment, the mice were 
sacrificed and the bacterial count in the lungs (a) and the blood (b) were analyzed (n =5). 
Box-and-whisker plots show the range and median of the bacterial count. LZD and TZD 
significantly decreased the bacterial count in the lungs compared with. The bacterial count in 
the blood was significantly decreased by high-VAN and TZD in comparison with the control. 
Additionally, only high-VAN significantly decreased the bacterial count in the blood in 




































Fig. 5. Histopathological examination of the lung specimens at 60 hours post-
inoculation: 
The mice were treated with normal saline q12h (control), 25 mg/kg of vancomycin q12h (low-
VAN), 110 mg/kg of vancomycin q12h (high-VAN), 120 mg/kg of linezolid q12h (LZD) or 20 
mg/kg of tedizolid q24h (TZD). Sixty hours post-inoculation, the mice were sacrificed. The 
representative data are shown (n = 3). In the LZD- as well as the TZD-treatment groups, the 
central bacterial colony zones (CBCZ) were eliminated from many abscess lesions (d, e). In 
contrast, such abscesses without the CBCZ were few in the low-VAN- (b) and the high-VAN-
treatment groups (c).
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Fig. 6. Plasma concentrations of the inflammatory cytokines: 
The mice were treated with normal saline q12h (control), 25 mg/kg of vancomycin q12h (low-
VAN), 110 mg/kg of vancomycin q12h (high-VAN), 120 mg/kg of linezolid q12h (LZD) or 20 
mg/kg of tedizolid q24h (TZD). The plasma concentrations of the inflammatory cytokines 
were evaluated at 26 hours post-inoculation i.e., 2 hours after the initial treatment (n=5 in 
each group). LZD and TZD significantly improved the plasma concentrations of TNF-alpha, 
IL-6 and MIP-2 in comparison with the (a, c, d). There were no significant differences in IL-
1beta (b). High-VAN significantly improved the concentrations of IL-6 (c). Asterisk, P < 0.05, 
versus control. Double asterisk, P < 0.01, versus control. Triple asterisk, P < 0.001 versus 
control.
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